{
    "clinical_study": {
        "@rank": "13304", 
        "arm_group": {
            "arm_group_label": "HAI with FOLFOX", 
            "arm_group_type": "Experimental", 
            "description": "Hepatic Artery Infusion with Oxaliplatin, 5FU, and Folinic Acid"
        }, 
        "brief_summary": {
            "textblock": "Deliver oxliplatin and 5-FU via HAI to breast cancer patients with liver-only or\n      liver-predominant metastases who have failed at least one line of systemic chemotherapy in\n      metastatic setting."
        }, 
        "brief_title": "Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Breast Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasm Metastasis"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this pilot study, the investigators will deliver oxliplatin and 5-FU via HAI to breast\n      cancer patients with liver-only or liver-predominant metastases who have failed at least one\n      line of systemic chemotherapy in metastatic setting. The investigators hypothesize that HAI\n      chemotherapy will be able to convert some patients to surgical resection candidates, or/and\n      to overcome chemo-resistance of liver metastases to systemic i.v.  chemotherapy for some\n      clinically fit, heavily pre-treated patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Performance status ECOG 0-2 and a life expectancy of >3 months.\n\n          2. Patients were required to have measurable disease in the liver, defined as lesions\n             measuring >1 cm in largest diameter on spiral-computed tomography (CT) or magnetic\n             resonance imaging (MRI)\n\n          3. Histologically confirmed metastatic advanced solid tumors involving the liver, liver\n             replacement less than 70%\n\n          4. No bevacizumab (avastin) use within 4 weeks prior to enrollment.\n\n          5. Absence of portal vein thrombosis\n\n          6. Not a surgical candidate or patients refuge surgery at the time of enrollment\n\n          7. Loss of response to at least 1 line of systemic chemotherapy in metastatic setting\n\n          8. An asymptomatic extra-hepatic disease is allowed, provided that the extent of the\n             metastatic disease in the liver represented the bulk of the metastatic disease.\n\n          9. History of liver-directed therapy is eligible at the investigator's discretion.\n\n         10. Adequate renal function with a calculated creatinine clearance greater than 60\n             mL/min.\n\n         11. Hepatic function as follows: Total Bilirubin \u22643 mg/dL, AST \u22645 times upper normal\n             reference value, or ALT \u2264 5 times upper normal reference value.\n\n         12. Adequate bone marrow function (ANC \u22651500 cells/uL; PLT \u2265 100,000 cells/uL) before\n             each therapy.\n\n         13. At least three weeks from previous immunotherapy, chemotherapy or radiotherapy before\n             being enrolled in this study.\n\n         14. All females in childbearing age MUST have a negative serum HCG test unless patients\n             have prior hysterectomy.\n\n        Exclusion Criteria:\n\n          1. Clinical or radiographic evidence of moderate amount of ascites.\n\n          2. History of cirrhosis with Child-Pugh class B or C.\n\n          3. Pregnant or lactating females.\n\n          4. Inability to complete informed consent process and adhere to protocol treatment plan\n             and follow-up requirements.\n\n          5. Patients receiving any other investigational agents.\n\n          6. Patients with bleeding diathesis (clinical bleeding, prothrombin time =/> 1.5 X upper\n             institutional normal value, INR =/> 1.5, activated partial thromboplastin time aPTT\n             =/> 1.5 X upper institutional normal value), active gastric or duodenal ulcer.\n\n          7. History of thrombophilia, recurrent DVTs, diagnosis of phospholipid syndrome.\n\n          8. Past or current history of malignancy other than breast cancer with the exception of\n             treated non-melanoma skin cancer or carcinoma in situ of the cervix, or other cancers\n             cured by local therapy alone and a DFS \u22655 years.\n\n          9. Concurrent severe illness such as active infection, or psychiatric illness/social\n             situations that would limit safety and compliance with study requirements.\n\n         10. Patients with clinically significant cardiovascular disease: myocardial infarction or\n             unstable angina within 6 months, New York Heart Association Grade II or greater\n             congestive heart failure, serious cardiac arrhythmia requiring medication, unstable\n             angina pectoris, clinically significant peripheral vascular disease\n\n         11. Patients have untreated brain metastasis requiring or leptomeningeal metastases."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01937507", 
            "org_study_id": "12-20"
        }, 
        "intervention": {
            "arm_group_label": "HAI with FOLFOX", 
            "description": "HAI with FOLFOX q 3 weeks", 
            "intervention_name": "HAI with FOLFOX", 
            "intervention_type": "Drug", 
            "other_name": "Hepatic Artery Infusion"
        }, 
        "intervention_browse": {
            "mesh_term": "Leucovorin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "September 3, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Goodyear", 
                    "country": "United States", 
                    "state": "Arizona", 
                    "zip": "85338"
                }, 
                "name": "Western Regional Medical Center Inc"
            }, 
            "investigator": {
                "last_name": "Jiaxin Niu, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pilot Study of Hepatic Arterial Infusion (HAI) With Oxaliplatin, Folinic Acid and 5 Fluorouracil (FOLFOX) in Heavily Pre-Treated Patients With Liver-Predominant Metastasis From Breast Cancer", 
        "overall_contact": {
            "email": "marci.pierog@ctca-hope.com", 
            "last_name": "Marci Pierog, RN", 
            "phone": "623 207-3000"
        }, 
        "overall_contact_backup": {
            "email": "india.hill@ctca-hope.com", 
            "last_name": "India Hill, CCRP", 
            "phone": "623 207-3000"
        }, 
        "overall_official": {
            "affiliation": "Western Regional Medical Center", 
            "last_name": "Jiaxin Niu, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "\u2022 To determine response rate (RR), time to intra-hepatic progression (TIP), time to extra-hepatic progression (TEP) of HAI with oxaliplatin/5-FU every three weeks in heavily pre-treated patients with advanced breast cancer with metastasis to the liver.", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01937507"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Western Regional Medical Center", 
            "investigator_full_name": "Jiaxin Niu", 
            "investigator_title": "Medical Oncologist", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Document the toxicity and tolerability of the therapy using the following CBC with differential, BUN, creatinine, liver function tests,CA 15-3, CA 27.29, Circulating tumor cells (CTCs)and Restaging radiographic studies (MRI or CT liver protocol).", 
            "measure": "\u2022 To document the toxicity, tolerability of the therapy in this population.", 
            "safety_issue": "Yes", 
            "time_frame": "one year"
        }, 
        "source": "Western Regional Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Western Regional Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}